← Back to Screener
InspireMD, Inc. (NSPR)
Price$1.35
Favorite Metrics
Price vs S&P 500 (26W)-48.54%
Price vs S&P 500 (4W)-30.40%
Market Capitalization$65.06M
All Metrics
Book Value / Share (Quarterly)$1.53
P/TBV (Annual)3.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)15.92%
Cash Flow / Share (Quarterly)$-0.82
Price vs S&P 500 (YTD)-26.80%
Gross Margin (TTM)26.34%
Net Profit Margin (TTM)-560.46%
EPS (TTM)$-0.84
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.84
Revenue Growth (5Y)13.51%
EPS (Annual)$-0.76
ROI (Annual)-88.69%
Gross Margin (Annual)21.49%
Net Profit Margin (5Y Avg)-378.02%
Cash / Share (Quarterly)$1.51
Revenue Growth QoQ (YoY)39.39%
ROA (Last FY)-68.38%
Revenue Growth TTM (YoY)-8.37%
EBITD / Share (TTM)$-0.82
ROE (5Y Avg)-75.32%
Operating Margin (TTM)-567.04%
Cash Flow / Share (Annual)$-0.87
P/B Ratio1.01x
P/B Ratio (Quarterly)1.58x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.26x
Net Interest Coverage (TTM)-69.08x
ROA (TTM)-93.57%
EPS Incl Extra (Annual)$-0.76
Current Ratio (Annual)5.28x
Quick Ratio (Quarterly)6.09x
3-Month Avg Trading Volume0.04M
52-Week Price Return-48.08%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.02
P/S Ratio (Annual)9.28x
Asset Turnover (Annual)0.15x
52-Week High$2.93
Operating Margin (5Y Avg)-384.92%
EPS Excl Extra (Annual)$-0.76
CapEx CAGR (5Y)38.01%
Tangible BV CAGR (5Y)42.11%
26-Week Price Return-44.56%
Quick Ratio (Annual)4.80x
13-Week Price Return-16.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.51x
Enterprise Value$1.656
Revenue / Share Growth (5Y)-63.71%
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)-42.02%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.35x
Pretax Margin (Annual)-455.79%
Cash / Share (Annual)$1.30
3-Month Return Std Dev51.01%
Gross Margin (5Y Avg)18.43%
Net Income / Employee (TTM)$-1
ROE (Last FY)-88.69%
Net Interest Coverage (Annual)-11.49x
EPS Basic Excl Extra (Annual)$-0.76
Receivables Turnover (TTM)3.58x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.84
Receivables Turnover (Annual)4.15x
ROI (TTM)-124.26%
P/S Ratio (TTM)10.41x
Pretax Margin (5Y Avg)-377.30%
Revenue / Share (Annual)$0.17
Tangible BV / Share (Annual)$2.09
Price vs S&P 500 (52W)-77.91%
Year-to-Date Return-24.16%
5-Day Price Return0.75%
EPS Normalized (Annual)$-0.76
ROA (5Y Avg)-56.41%
Net Profit Margin (Annual)-456.63%
Month-to-Date Return-17.18%
Cash Flow / Share (TTM)$-0.79
EBITD / Share (Annual)$-0.76
Operating Margin (Annual)-478.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-75.32%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.84
P/TBV (Quarterly)1.45x
P/B Ratio (Annual)1.90x
Inventory Turnover (TTM)1.93x
Pretax Margin (TTM)-559.66%
Book Value / Share (Annual)$1.36
Price vs S&P 500 (13W)-17.35%
Beta1.00x
Revenue / Share (TTM)$0.09
ROE (TTM)-124.26%
52-Week Low$1.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.11
4.11
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NSPRInspireMD, Inc. | 10.41x | 13.51% | 26.34% | -567.04% | $1.35 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
InspireMD is a U.S.-based medical device company specializing in proprietary MicroNet stent platform technology for treating complex vascular and coronary disease. Its primary revenue driver is the CGuard carotid Embolic Prevention System, which combines the company's proprietary MicroNet technology with a self-expandable stent for carotid artery applications. The company also offers the MGuard Prime Embolic Protection System and maintains operations across Europe and Russia.